Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation

Journal of Molecular Biology

Volumn 426, Issue 2, 2014, Pages 332-346

  Lange, Ingo ^a   Geerts, Dirk ^b   Feith, David J ^c   Mocz, Gabor ^d   Koster, Jan ^e   Bachmann, André S ^a,f  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF HAWAII   (United States)

Author keywords

docking simulation; ornithine decarboxylase; pediatric neuroblastoma; protein protein interaction; sepiapterin reductase

Indexed keywords

DIMER; MONOMER; ORNITHINE DECARBOXYLASE; SEPIAPTERIN REDUCTASE; SMALL INTERFERING RNA;

ARTICLE; CELL PROLIFERATION; COMPUTER MODEL; ENZYME ACTIVITY; ENZYME CONFORMATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR DOCKING; MOLECULAR INTERACTION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIMULATION;

4′,6-DIAMIDINO-2-PHENYLINDOLE; BLOCKING PEPTIDE; BP; DAPI; DOCKING SIMULATION; FBS; FETAL BOVINE SERUM; HEK293; HUMAN EMBRYONIC KIDNEY 293; NB; NEUROBLASTOMA; NITRIC OXIDE SYNTHASE; NOS; ODC; ORNITHINE DECARBOXYLASE; PBS; PEDIATRIC NEUROBLASTOMA; PHOSPHATE-BUFFERED SALINE; PROTEIN-PROTEIN INTERACTION; SEPIAPTERIN REDUCTASE; SPR;

ALCOHOL OXIDOREDUCTASES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NEUROBLASTOMA; NEURONS; ORNITHINE DECARBOXYLASE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN MULTIMERIZATION; SURVIVAL ANALYSIS;

EID: 84891835019     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2013.09.037     Document Type: Article

References (62)

1. M. Auvinen, K. Jarvinen, A. Hotti, J. Okkeri, J. Laitinen, and O.A. Janne et al. Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc Int J Biochem Cell Biol 35 2003 496 521
2. M. Auvinen, A. Paasinen, L.C. Andersson, and E. Holtta Ornithine decarboxylase activity is critical for cell transformation Nature 360 1992 355 358
3. R.A. Casero, and L.J. Marton Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases Nat Rev Drug Discov 6 2007 373 390
4. A.E. Pegg, and D.J. Feith Polyamines and neoplastic growth Biochem Soc Trans 35 2007 295 299
5. J.A. Nilsson, U.B. Keller, T.A. Baudino, C. Yang, S. Norton, and J.A. Old et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation Cancer Cell 7 2005 433 444
6. A.S. Bachmann, D. Geerts, and G. Sholler Neuroblastoma: ornithine decarboxylase and polyamines are novel targets for therapeutic intervention M.A. Hayat, Pediatr Cancer Neuroblastoma Diagn Ther Prognosis vol. 1 2012 Springer Heidelberg 91 103
7. N.F. Evageliou, and M.D. Hogarty Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma Clin Cancer Res 15 2009 5956 5961
8. D. Geerts, J. Koster, D. Albert, D.L. Koomoa, D.J. Feith, and A.E. Pegg et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification Int J Cancer 126 2010 2012 2024
9. M.D. Hogarty, M.D. Norris, K. Davis, X. Liu, N.F. Evageliou, and C.S. Hayes et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma Cancer Res 68 2008 9735 9745
10. D.L. Koomoa, D. Geerts, I. Lange, J. Koster, A.E. Pegg, and D.J. Feith et al. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma Int J Oncol 42 2013 1219 1228
11. D.L. Koomoa, L.P. Yco, T. Borsics, C.J. Wallick, and A.S. Bachmann Ornithine decarboxylase inhibition by {alpha}-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma Cancer Res 68 2008 9825 9831
12. R.J. Rounbehler, W. Li, M.A. Hall, C. Yang, M. Fallahi, and J.L. Cleveland Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma Cancer Res 69 2009 547 553
13. C.J. Wallick, I. Gamper, M. Thorne, D.J. Feith, K.Y. Takasaki, and S.M. Wilson et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells Oncogene 24 2005 5606 5618
14. K. Samal, P. Zhao, A. Kendzicky, L.P. Yco, H. McClung, and E.W. Gerner et al. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport Int J Cancer 133 2013 1323 1334
15. A.S. Bachmann The role of polyamines in human cancer: prospects for drug combination therapies Hawaii Med J 63 2004 371 374
16. A.S. Bachmann, and V.A. Levin Clinical applications of polyamine-based therapeutics P.M. Woster, R.A. Casero, Polyamine Drug Discovery 2012 Royal Society of Chemistry 257 276
17. L.D. Gamble, M.D. Hogarty, X. Liu, D.S. Ziegler, G. Marshall, and M.D. Norris et al. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma Front Oncol 2 2012 162
18. X. Lu, A. Pearson, and J. Lunec The MYCN oncoprotein as a drug development target Cancer Lett 197 2003 125 130
19. W. Lutz, M. Stohr, J. Schurmann, A. Wenzel, A. Lohr, and M. Schwab Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells Oncogene 13 1996 803 812
20. G.M. Brodeur Neuroblastoma: biological insights into a clinical enigma Nat Rev Cancer 3 2003 203 216
21. J.M. Maris Recent advances in neuroblastoma N Engl J Med 362 2010 2202 2211
22. J.R. Park, A. Eggert, and H. Caron Neuroblastoma: biology, prognosis, and treatment Hematol Oncol Clin North Am 24 2010 65 86
23. S. Matsufuji, T. Matsufuji, Y. Miyazaki, Y. Murakami, J.F. Atkins, and R.F. Gesteland et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme Cell 80 1995 51 60
24. O. Cohavi, D. Tobi, and G. Schreiber Docking of antizyme to ornithine decarboxylase and antizyme inhibitor using experimental mutant and double-mutant cycle data J Mol Biol 390 2009 503 515
25. Y.C. Liu, D.H. Hsu, C.L. Huang, Y.L. Liu, G.Y. Liu, and H.C. Hung Determinants of the differential antizyme-binding affinity of ornithine decarboxylase PLoS One 6 2011 e26835
26. Y.C. Liu, Y.L. Liu, J.Y. Su, G.Y. Liu, and H.C. Hung Critical factors governing the difference in antizyme-binding affinities between human ornithine decarboxylase and antizyme inhibitor PLoS One 6 2011 e19253
27. K.L. Su, Y.F. Liao, H.C. Hung, and G.Y. Liu Critical factors determining dimerization of human antizyme inhibitor J Biol Chem 284 2009 26768 26777
28. A.E. Pegg Regulation of ornithine decarboxylase J Biol Chem 281 2006 14529 14532
29. P. Coffino Antizyme, a mediator of ubiquitin-independent proteasomal degradation Biochimie 83 2001 319 323
30. P. Coffino Regulation of cellular polyamines by antizyme Nat Rev Mol Cell Biol 2 2001 188 194
31. U. Mangold The antizyme family: polyamines and beyond IUBMB Life 57 2005 671 676
32. S. Albeck, O. Dym, T. Unger, Z. Snapir, Z. Bercovich, and C. Kahana Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function Protein Sci 17 2008 793 802
33. C. Kahana Antizyme and antizyme inhibitor, a regulatory tango Cell Mol Life Sci 66 2009 2479 2488
34. U. Mangold Antizyme inhibitor: mysterious modulator of cell proliferation Cell Mol Life Sci 63 2006 2095 2101
35. R.R. Olsen, and B.R. Zetter Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer Mol Cancer Res 9 2011 1285 1293
36. L. Chen, Y. Li, C.H. Lin, T.H. Chan, R.K. Chow, and Y. Song et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma Nat Med 19 2013 209 216
37. E.R. Werner, N. Blau, and B. Thony Tetrahydrobiopterin: biochemistry and pathophysiology Biochem J 438 2011 397 414
38. R.A. Hillary, and A.E. Pegg Decarboxylases involved in polyamine biosynthesis and their inactivation by nitric oxide Biochim Biophys Acta 1647 2003 161 166
39. J. Friedman, E. Roze, J.E. Abdenur, R. Chang, S. Gasperini, and V. Saletti et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy Ann Neurol 71 2012 520 530
40. M. Sharma, D.M. Maraganore, J.P.A. Ioannidis, O. Riess, J.O. Aasly, and G. Annesi et al. Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease Neurobiol Aging 32 2011 2108.e1 2108.e5
41. L. Giot, J.S. Bader, C. Brouwer, A. Chaudhuri, B. Kuang, and Y. Li et al. A protein interaction map of Drosophila melanogaster Science 302 2003 1727 1736
42. J.J. Almrud, M.A. Oliveira, A.D. Kern, N.V. Grishin, M.A. Phillips, and M.L. Hackert Crystal structure of human ornithine decarboxylase at 2.1 Å resolution: structural insights to antizyme binding J Mol Biol 295 2000 7 16
43. G. Auerbach, A. Herrmann, M. Gutlich, M. Fischer, U. Jacob, and A. Bacher et al. The 1.25 Å crystal structure of sepiapterin reductase reveals its binding mode to pterins and brain neurotransmitters EMBO J 16 1997 7219 7230
44. A.D. Kern, M.A. Oliveira, P. Coffino, and M.L. Hackert Structure of mammalian ornithine decarboxylase at 1.6 Å resolution: stereochemical implications of PLP-dependent amino acid decarboxylases Structure 7 1999 567 581
45. J. Fernandez-Recio, M. Totrov, C. Skorodumov, and R. Abagyan Optimal docking area: a new method for predicting protein-protein interaction sites Proteins 58 2005 134 143
46. A. Tovchigrechko, and I.A. Vakser GRAMM-X public web server for protein-protein docking Nucleic Acids Res 34 2006 W310 W314
47. A.J. Lopez-Contreras, B.L. Sanchez-Laorden, B. Ramos-Molina, M.E. de la Morena, A. Cremades, and R. Penafiel Subcellular localization of antizyme inhibitor 2 in mammalian cells: influence of intrinsic sequences and interaction with antizymes J Cell Biochem 107 2009 732 740
48. A.E. Pegg Regulation of ornithine decarboxylase J Biol Chem 281 2006 14529 14532
49. D.L. Koomoa, T. Borsics, D.J. Feith, C.C. Coleman, C.J. Wallick, and I. Gamper et al. Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma Mol Cancer Ther 8 2009 2067 2075
50. D.L. Koomoa, R.C. Go, K. Wester, and A.S. Bachmann Expression profile of PRAF2 in the human brain and enrichment in synaptic vesicles Neurosci Lett 436 2008 171 176
51. P. Fardin, A. Barla, S. Mosci, L. Rosasco, A. Verri, and R. Versteeg et al. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients Mol Cancer 9 2010 185
52. J.E. Gawecka, D. Geerts, J. Koster, M.J. Caliva, F.J. Sulzmaier, and J. Opoku-Ansah et al. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma Int J Cancer 131 2012 1556 1568
53. D. Geerts, C.J. Wallick, D.L. Koomoa, J. Koster, R. Versteeg, and R.C. Go et al. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation Clin Cancer Res 13 2007 6312 6319
54. I. Revet, G. Huizenga, A. Chan, J. Koster, R. Volckmann, and P. van Sluis et al. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma Exp Cell Res 314 2008 707 719
55. E.W. Gerner, and F.L. Meyskens Polyamines and cancer: old molecules, new understanding Nat Rev Cancer 4 2004 781 792
56. G. Sholler, E. Gerner, G. Bergendahl, B.J. LaFleur, A. VanderWerff, and T. Ashilkaga et al. A phase I trial of DFMO as a single agent and in combination with etoposide in patients with refractory or recurrent neuroblastoma Annual Meeting of the American Association for Cancer Research (AACR) 2013 LB-179 [Washington, D.C.]
57. E. Lohmann, C. Koroglu, H.A. Hanagasi, B. Dursun, E. Tasan, and A. Tolun A homozygous frameshift mutation of sepiapterin reductase gene causing parkinsonism with onset in childhood Parkinsonism Relat Disord 18 2012 191 193
58. N.M. Lewandowski, S. Ju, M. Verbitsky, B. Ross, M.L. Geddie, and E. Rockenstein et al. Polyamine pathway contributes to the pathogenesis of Parkinson disease Proc Natl Acad Sci U S A 107 2010 16970 16975
59. E. Katchalski-Katzir, I. Shariv, M. Eisenstein, A.A. Friesem, C. Aflalo, and I.A. Vakser Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques Proc Natl Acad Sci U S A 89 1992 2195 2199
60. 14C]ornithine Methods Mol Biol 79 1998 41 44
61. T. Barrett, D.B. Troup, S.E. Wilhite, P. Ledoux, D. Rudnev, and C. Evangelista et al. NCBI GEO: archive for high-throughput functional genomic data Nucleic Acids Res 37 2009 D885 D890
62. V. Bewick, L. Cheek, and J. Ball Statistics review 12: survival analysis Crit Care 8 2004 389 394